No evidence of IFN-γ increase in the serum of HIV-positive and healthy subjects after subcutaneous injection of a non-fermented Viscum album L. extract

Natural Immunity

Volumn 16, Issue 4, 1998, Pages 157-164

  Stoss, Matthias ^a,d   Gorter, Robert W ^a,b,c,d  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Medizinische Sektion am Goetheanum   (Switzerland)

Author keywords

HIV positives; IFN levels, serum; Immunomodulation; Iscador ; Viscum album L.

Indexed keywords

GAMMA INTERFERON; PLANT EXTRACT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT PERIOD; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VISCUM ALBUM;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HIV SEROPOSITIVITY; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; MALE; MIDDLE AGED; MISTLETOE; PLANT EXTRACTS; PLANT PROTEINS; PLANTS, MEDICINAL;

EID: 0032459388     PISSN: 10188916     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069440     Document Type: Article

References (34)

1. Becker H: Botany of European mistletoe (Viscum album L.). Oncology 1986;43(suppl 1):2-7.
2. Franz H: Inhaltsstoffe der Mistel (Viscum album L.) als potentielle Arzneimittel. Pharmazie 1985;40/2: 97-104.
3. Steiner R: Spiritual Science and Medicine. London, Rudolf Steiner Press, 1975, pp 248-253.
4. Stoss M, Peter E, Schnelle M, Werner M, Gorter RW: Viscum album QuFrF in HIV-positives and AIDS patients. 12th World AIDS Conference Geneva (Switzerland), June 28 to July 3, 1998, Clinical Science. Bologna, Monduzzi Editore International Proceedings Division, 1998, pp 467-472.
5. Stoss M, van Wely M, Musielsky H, Gorter RW: Local inflammatory reactions and other parameters during subcutaneous mistletoe therapy in HIV-positive patients and HIV-negative subjects. Arzneimittelforschung 1999;4:366-373.
6. Gorter RW, van Wely M, Stoss M, Wollina U: Subcutaneous infiltrates induced by injection of mistletoe extracts (Iscador®). Am J Ther 1998;5: 181-187.
7. van Wely M, Stoss M, Gorter RW: Open-label phase-II-trial to document immunomodulating and anti-HIV activities of Iscador Qu FrF in HIV-positives. 2nd European Conference on Experimental AIDS Research, Stockholm, 1997.
8. Gorter RW, Stein J, Stoss M, Linder M: Prospektive, longitudinale, dosis-eskalierende, randomisierte Phase-I/II-Studie mit Iscador® QuFrF und Iscador® Qu Spezial mit HIV-Positiven, Krebspatienten und gesunden, nichtrauchenden Probanden. Forsch Komplementärmed 1996;3:169-175.
9. Joller PW, Menrad JM, Schwarz T, Pfüller U, Parnham MJ, Weyhenmeyer R: Stimulation of cytokine production via a special standardized mistletoe preparation in an vitro human skin bioassay. Arzneimittelforschung 1996;46:649-653.
10. Nikolai G, Friedl P, Werner M, Zänker KS: Donor-dependent and dose-dependent variations in the induction of T lymphocyte locomotion in a three-dimensional collagen matrix system by a mistletoe preparation (Iscador). Anticancer Drugs 1997;8(suppl 1):61-64.
11. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 1995;14:295-304.
12. Stein GM, Meink H, Durst J, Berg PA: Release of cytokines by a fermented lectin-1 (ML-I) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumour patients. Eur J Clin Pharmacol 1996; 151:247-252.
13. Dumont S, Poindron P, Ribereau-Gayon G, Jung ML, Muller CD, Frantz M, Anton R: Mistletoe lectins: Inhibition of the cytotoxicity by sugars and stimulation of the production of cytokines by cultured human monocytes. Interlec 16. 16th International Lectin Meeting, Toulouse, 1995.
14. Müller EA, Anderer FA: A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon γ inducer. Cancer Immunol Immunother 1990;32:221-227.
15. Schultze JL, Stettin A, Berg PA: Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klin Wochenschr 1991;69:397-403.
16. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, Tamburini M, Villa ML, Fabiani M, Milazzo F, Clerici M: Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 1996;10:1535-1542.
17. Sinicco A, Biglino A, Sciandra M, Forno B, Pollono AM, Raiteri R, Gionannini P: Cytokine network and acute primary HIV-I infection. AIDS 1993;7:1167-1172.
18. Bolinger AM, Taeubel MA: Recombinant interferon gamma for the treatment of chronic granulomatous disease and other disorders. Clin Pharmacol 1992;11:834-850.
19. Satake I, Tari K, Nakagomi K, Ozawa K: Feasibility and pharmacokinetics of continuous subcutaneous infusion of low-dose interferon-gamma: A pilot study. Jpn J Clin Oncol 1993;23:356-362.
20. Tilg H, Vogel W, Tratkiewicz J, Aulizky WE, Herold M, Gruber M, Geissler D, Umlauft F, Judmeier G, Schwulera U: Pilot study of natural human interleukin-2 in patients with chronic hepatitis B: Immunomodulatory and antiviral effects. J Hepatol 1993;19/2:259-267.
21. Bajetta E, Del-Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G: Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998;4/1:75-85.
22. Zanussi S, Simonelli C, D'Andrea M, Caffau C, Clerici M, Tierlli U: CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol 1996;105:220-224.
23. Galanaud P: The in vivo expression of cytokine genes in humans. J Lipid Mediat Cell Signal 1994;9:37-41.
24. Emilie D, Mailott MC, Nicolas JF, Fior R, Galanaud P: Antagonistic effect of interferon-γ on tat-induced transactivation of HIV long terminal repeat. J Biol Chem 1992;29: 20565-20570.
25. Fan SX, Turpin JA, Aranovitz JR, Meltzer MS: Interferon-γ protects primary monocytes against infection with human immunodeficiency virus type 1. J Leukoc Biol 1994;56: 362-368.
26. Yamashiki M, Kosaka Y, Nishimura A, Watanabe S, Nomoto M, Ichida F: Analysis of serum cytokines in primary biliary cirrhosis patients and healthy adults. J Clin Lab Anal 1998; 12/2:77-82.
27. Jäggi C, Musielski H, Urech K, Schaller G: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 1995; 45:905-909.
28. Schaller G, Urech K, Giannattasio M: Cytotoxicity of different viscotoxins and extracts from the European subspecies of Viscum album L. Phytother Res 1996; 10:473-477.
29. van Wely M, Stoss M, Gorter RW: Toxicity of a standardized mistletoe extract in immunocompromised and in healthy individuals. Am J Ther 1999;6:37-43.
30. Thavasu PW, Longhurst S, Joel SP, Selvin ML, Balkwill FR: Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 1992;153:115-124.
31. Bos JD, Kapsenberg L: The skin immune system. Its cellular constituents and their interactions. Immunol Today 1986;7+8/7:235-240.
32. Vecchi A, Cavanna L, Avanzini P, Callea V, Velardi A, Albi N, Tartoni P, Bensi L, Valentini P, Longo R, Sacchi S: In vivo biological response following low dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. Eur J Haematol 1996;57:33-37.
33. Klopp R, Niemer W, Schmid W, Werner M, Gorter RW, Stoss M: A study of the local responses after subcutaneous injections of Viscum album (Iscador®). Submitted.
34. Friedberg D, Bryant J, Shannon W, Whiteside TL: In vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation. Clin Diagn Lab Immunol 1994;1/3:261-268.